Vivesto AB (SE:VIVE)
:VIVE
Want to see SE:VIVE full AI Analyst Report?
VIVE Stock Chart & Stats
kr0.08
>-kr0.01(-0.59%)
At close: 4:00 PM EST
kr0.08
>-kr0.01(-0.59%)
Day’s Range― - ―
52-Week Rangekr7.00 - kr27.82
Previous CloseN/A
Volume772.68K
Average Volume (3M)410.92K
Market Cap
kr188.21M
Enterprise Valuekr90.48M
Total Cash (Recent Filing)kr31.48M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding11,071,369
10 Day Avg. Volume214,919
30 Day Avg. Volume410,918
Financial Highlights & Ratios
PEG Ratio8.38
Price to Book (P/B)58.31
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Niche Oncology Drug‑delivery FocusA focused business model on improving delivery/formulation of anticancer drugs is a durable strategic niche. It leverages technical specialization versus broad drug discovery, supports differentiated clinical value propositions, and can enable partnership or licensing paths rather than relying solely on internal commercialization.
Low Financial LeverageA low debt load provides structural financial flexibility despite operating losses. Manageable leverage reduces near-term default and interest burden risk, allowing management to prioritize R&D and regulatory programs without heavy debt-driven cash outflows that could otherwise accelerate capital strain.
Improving Cash‑burn TrendA material year‑over‑year reduction in operating cash burn signals improving operational efficiency or program pacing. While still negative, this durable improvement can extend runway, reduce financing frequency, and suggests management is addressing cash consumption in ways that could support longer‑term program continuity.
Bears Say
Persistent Net LossesSustained negative earnings and cash outflows indicate the company is not yet generating profit and remains reliant on external funding. Over months, continued losses will erode capital, constrain strategic options, and make it harder to scale operations or invest in late‑stage development without fresh financing.
No Recent Commercial RevenueA recent absence of reported revenue removes an independent commercial validation and leaves the firm dependent on development milestones or financing. This structural lack of recurring sales makes margin sustainability, cash generation, and business scalability highly uncertain over the medium term.
Eroding Shareholder EquityA large decline in equity over several years reflects accumulated losses and weaker capital cushions. This reduces the buffer against future setbacks, limits borrowing capacity, and increases the probability that management will need dilutive financing or partnerships, which can affect long‑term strategic autonomy.
Vivesto AB News
VIVE FAQ
What was Vivesto AB’s price range in the past 12 months?
Vivesto AB lowest stock price was kr7.00 and its highest was kr27.82 in the past 12 months.
What is Vivesto AB’s market cap?
Vivesto AB’s market cap is kr188.21M.
When is Vivesto AB’s upcoming earnings report date?
Vivesto AB’s upcoming earnings report date is Aug 13, 2026 which is in 80 days.
How were Vivesto AB’s earnings last quarter?
Vivesto AB released its earnings results on May 07, 2026. The company reported -kr0.838 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.838.
Is Vivesto AB overvalued?
According to Wall Street analysts Vivesto AB’s price is currently Overvalued.
Does Vivesto AB pay dividends?
Vivesto AB does not currently pay dividends.
What is Vivesto AB’s EPS estimate?
Vivesto AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vivesto AB have?
Vivesto AB has 11,071,369 shares outstanding.
What happened to Vivesto AB’s price movement after its last earnings report?
Vivesto AB reported an EPS of -kr0.838 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.235%.
Which hedge fund is a major shareholder of Vivesto AB?
Currently, no hedge funds are holding shares in SE:VIVE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vivesto AB
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.
Technical Analysis
AlzeCure Pharma AB
―
Gabather AB
―
Klaria Pharma Holding AB
―
Nanexa AB
―
Enorama Pharma AB
―